The startup Kairos Discovery, created at the end of 2022, is developing a portfolio of drug candidates for potential oncology applications. On May 2 it announced that it had received €1.2 million from business angels specializing in healthcare, such as Health Angels Rhône-Alpes (HARA) and 33 Californie, individual investors and financial institutions (including Bpifrance) and grants. These resources will be used for the pre-clinical development of its first drug candidate, a first-in-class protein kinase CK2 inhibitor.

Launched in 2021, Maddie targets paramedical professionals (physiotherapists, occupational therapists, speech therapists, orthoptists, midwives, nurses and so on) offering them a range of services starting at €39 a month. This “all-in-one solution for independent healthcare professionals for a prosperous, well-managed practice”, as they describe it on their website, provides digital tools to improve the online indexing of the practice, a digital calendar, online appointment booking, easier schedule management and more. Unveiled on May 2, this €1.1 million fundraising round was carried out with business angels, healthcare professionals who are customers of the platform, and Bpifrance. Using these funds, Maddie will continue to develop its solution by offering a payment module which will be integrated into the platform in the near future.

On May 9, six years after it was established, REGEnLIFE (based in Montpelier in the south of France) completed a new €3 million fundraising operation with its historical associates and new private investors. These funds will help REGEnLIFE pursue the development and clinical trials of the first medical technology designed to target the brain-gut axis in the treatment of neurodegenerative diseases, notably Alzheimer’s disease and concussion.

On May 10, the Rennes-based startup created in 2018 carried out a financial transaction of €3.5 million with its historical investors Epopée Gestion and Breizh Up, but also with Vivalto SAS for the first time. Simango has designed around forty digital and immersive healthcare e-learning modules. These serious game-type training programs last around thirty minutes and are available on any type of media.

The startup wishes to use these funds to target new markets (social medicine, psychiatry, nursing homes, independent physicians and so on). It is starting to penetrate Belgium and Morocco, and discussions are underway about Switzerland and Canada.

Biophytis was delighted with the success of its €2.3 million fundraising campaign which took place on May 11. Professional investors participated to the tune of €1.9 million, and private investors with €0.4 million, via the PrimaryBid platform. The biotech company, which was founded in 2006, develops treatments aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including respiratory failure in patients suffering from COVID-19. This transaction will serve to finance the regulatory applications in Europe and the USA for Sarconeos (BIO101), used to treat severe forms of COVID-19.

98% of laboratories and 65% of French pharmacies use Faks management software for tasks linked to commercial after-sales relations with their suppliers. The business will target the European market, using the €5 million raised with Connect Ventures, Seedcamp and Cocoa VC, announced on May 17. Founded in 2020, the startup has developed an application, available on the web and via cellphones, that simplifies and digitizes proof-of-sale documents, product promotion and complaints.

On May 22, the Grenoble-based startup announced that it had raised €5.3 million with groups of business angels and family offices (Monaco Molecular Roc Fund, BADGE, Angelor via its investment company Simba Santé 3, SAMBA, Rhône Vallée Angels, Grenoble Angels, 33 Californie, Momentum Biotech), as well as BPI, ANR, and the Auvergne Rhône Alpes region. These funds are supplemented by direct financing of €1.1 million from the hospitals in charge of the clinical trials, and by a bank loan.

Mag4Health is democratizing magnetoencephalographs (MEGs), which are imagers that record all neuronal activity in the form of a 3D film. This financing will make it possible to produce 12 MEGs in 2023 and 2024 for the first clients, to complete clinical trials for certification in Europe, and to file the certification dossier in the USA. Founded in April 2021, Mag4Health is preparing access to concussion diagnosis markets and the early diagnosis of degenerative dementia, notably Alzheimer’s disease.

Ever since its launch in 2013, Paris- and Boston-based TISSIUM has specialized in the development and commercialization of a unique platform of biopolymers designed to respond to various unsatisfied clinical requirements, including the atraumatic reparation and reconstruction of tissues. On May 23, the medtech company announced a Series D fundraising round of €50 million with new and existing investors, including the Fonds Stratégique des Transitions managed by ISALT, Mérieux Développement, Cathay Health, Crédit Mutuel Innovation and Sofinnova Partners. This financing will allow TISSIUM to pursue its development plan and to finance the marketing of its first products for peripheral nerve repair and hernia treatment in the USA, as well as the expansion of its product portfolio and its technological platform.

On May 31, the startup announced a €2 million seed financing deal with Sofinnova Partners. BrightHeart technology combines high-level expertise in fetal echocardiography with the power of AI. The tool developed is designed to help healthcare professionals improve the detection of critical congenital heart disease in utero, during follow-up ultrasounds performed during pregnancy. The funds will be used to strengthen R&D, prepare regulatory submissions and facilitate the business’s expansion.